- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Orexo AB (ORX)
The Orexo AB share price today is 15.2, view ST ORX stock exchange data. Track the latest Orexo AB share price with real-time updates on ORX stock performance including market cap, day range, 52-week range and dividend yield. Access ORX charts, earnings dates and analyst estimates to support your investment decisions.
Currency in SEK
15.2
0.0(0.00%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.8
16.5
52 wk Range
14.0
43.4
ORX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.816.5
52 wk Range
14.043.4
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ORX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral
Orexo AB Earnings Call Summary for Q2/2026
- Orexo reported Q2 net loss of SEK 102.5M on revenues of SEK 3.5M; shares plunged 19% to $17.4, near 52-week low of $16.8.
- Operating expenses hit SEK 107M due to restructuring costs including SEK 20M GAIA settlement; normalized quarterly run rate expected at SEK 60M.
- Company ended quarter with SEK 233M cash position; management reviewing financing options amid cash burn concerns and potential equity raise.
- Izipry nasal spray remains on track for September 2026 FDA filing with approval expected by end of Q1 2027; OX640 anaphylaxis study planned Q4 2026.
- DOJ settlement discussions ongoing with no formal term sheet; management seeks to avoid $10M+ in legal costs through negotiated resolution.
Last Updated: 16-07-2026, 06:44 pm
Read Full TranscriptEarnings
Latest Release
16-07-2026
EPS / Forecast
-2.20 / -1.60
Revenue / Forecast
3.5M / 10.1M
Compare ORX to Peers and Sector
Metrics to compare | ORX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | 57.7x | −0.4x | |
PEG Ratio | 0.00 | −0.75 | 0.00 | |
Price/Book | 2.0x | 5.0x | 2.6x | |
Price / LTM Sales | 32.0x | 4.9x | 3.0x | |
Upside (Analyst Target) | 74.3% | 109.3% | 57.2% | |
Fair Value Upside | Unlock | 11.3% | 9.6% | Unlock |
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Orexo AB (ORX) Share Price Today?
The Orexo AB share price today is 15.2.
What is the current Orexo AB (ORX) share price and day range?
As of 25-07-2026, the Orexo AB share price is 15.2, with a previous close of 15.2. The share price has ranged from 14.8 to 16.5 today, while the 52-week range spans from 14.0 to 43.4.
What Is the Orexo AB Market Cap?
As of today, Orexo AB market cap is 532.21M.
What Is the Orexo AB (ORX) Share Price Target?
The average 12-month share price target for Orexo AB is 26.5, with a high estimate of 26.5 and a low estimate of 26.5. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +74.34% Upside potential.
What Is Orexo AB's Earnings Per Share (TTM)?
The Orexo AB EPS (TTM) is -12.2.
When Is the Next Orexo AB Earnings Date?
Orexo AB will release its next earnings report on 22-10-2026.
From a Technical Analysis Perspective, Is ORX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Orexo AB Trade On?
Orexo AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Orexo AB?
The stock symbol for Orexo AB is "ORX."
How Many Times Has Orexo AB Stock Split?
Orexo AB has split 2 times.
How Many Employees Does Orexo AB Have?
Orexo AB has 61 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.